Hypertension
Conditions
Interventions
Dose of telmisartan increased from 40mg/d to 80mg/d (6-month administration).
Hydrochlorothiazide 12.5mg/d add to telmisartan 40mg/d (6-month administration).
Eplerenone 50mg/d add to telmisartan 40mg
Sponsors
Department of Internal Medicine, Graduate School of Medical Science, Kanazawa University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1.Hypertensive patient who administrated telmisartan for three months or more, and still blood pressure is higher than Guideline target level. 2.Patient who have one or more metabolic syndorome risk factor (obesity,IGT etc.)
Exclusion criteria
Exclusion criteria: 1. Pregnant or lactating women 2. Malignant hypertension and secondary hypertension 3. Diabetes mellitus patient with unstable glycemic control whose HbA1c is more than 8.0%, or complicated with diabetic nephropathy more than stage 2 4. Patient who is intoleramce or allergic aginst hydrochlorothiazide 5. FBG is more than 400mg/dL 6. patient who has kidney or liver dysfunction
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Systolic and diastolic blood pressure | — |
Secondary
| Measure | Time frame |
|---|---|
| home blood pressure, serum 1ipids, FBG, HbA1c, IRI, hsCRP, adipocytokine, plasma renin activity, plasma aldosterone | — |
Countries
Japan
Contacts
Public ContactYoshiyu Takeda
Kanazawa University Hospital Department of Endocrinology and Metabolism
Outcome results
None listed